How Much Does Jatenzo Cost in New Hampshire?

Jatenzo Retail Pricing in New Hampshire

The average cash price for Jatenzo at New Hampshire retail pharmacies sits at roughly $900 per month in 2026, matching the manufacturer list price set by Tolmar Pharmaceuticals. This figure applies to patients paying entirely out of pocket without insurance or discount programs.

Jatenzo received FDA approval in March 2019 as the first oral testosterone undecanoate capsule for adult males with hypogonadism. The key trial by Swerdloff et al. (2020) enrolled 166 hypogonadal men and demonstrated that 87% of subjects achieved average testosterone levels within the normal range (300 to 1 to 100 ng/dL) at the 237 mg twice-daily dose. That efficacy profile supports Jatenzo's positioning as an alternative to injectable testosterone, but the monthly cost remains a significant barrier for many New Hampshire patients. Prices can vary by $50 to $100 between pharmacies in cities like Manchester, Nashua, and Concord. Calling ahead or using price-comparison tools before filling the prescription is worth the effort.

The drug is classified as a Schedule III controlled substance under federal law, which means refills are limited and prescriptions cannot exceed a 90-day supply without a new order. This scheduling also affects how pharmacies handle transfers between locations.

New Hampshire Medicaid and Jatenzo Coverage

New Hampshire Medicaid does not cover Jatenzo as of 2026. Patients enrolled in NH Medicaid who need testosterone replacement therapy are typically directed toward generic injectable formulations such as testosterone cypionate or testosterone enanthate, which cost between $30 and $75 per month.

The exclusion of Jatenzo from the New Hampshire Medicaid formulary reflects a broader pattern across state Medicaid programs. Oral testosterone undecanoate carries a substantially higher per-month cost compared to injectable alternatives, and most state formulary committees have determined that the clinical benefit does not justify the price differential for their covered populations. The Endocrine Society's 2018 clinical practice guideline recommends testosterone replacement for confirmed hypogonadism but does not mandate any specific formulation, giving payers flexibility to prefer lower-cost options.

Patients on NH Medicaid who have a documented medical reason for avoiding injections (needle phobia, anticoagulant therapy, or injection-site complications) may attempt a formulary exception request. Success rates for such exceptions vary, and documentation from the prescribing clinician must establish medical necessity for the oral route specifically. A denial can be appealed through New Hampshire's Medicaid managed care grievance process, though approvals remain uncommon for brand-name oral testosterone.

Commercial Insurance Coverage in New Hampshire

Several commercial insurers operating in New Hampshire do cover Jatenzo, though almost all require prior authorization and step therapy. Plans from Anthem Blue Cross Blue Shield, Cigna, Harvard Pilgrim Health Care, and Ambetter may include Jatenzo on specialty or non-preferred brand tiers.

Prior authorization for Jatenzo typically requires three pieces of documentation: a confirmed diagnosis of male hypogonadism based on at least two morning serum testosterone levels below 300 ng/dL, evidence that the patient has tried (or has a contraindication to) injectable testosterone, and a prescription from an endocrinologist or urologist. Some plans accept primary care prescriptions if the diagnostic criteria are clearly met. The American Urological Association endorses testosterone therapy for symptomatic men with consistently low serum testosterone, a standard that aligns with most insurer criteria.

Copays for patients whose plans do cover Jatenzo range from $50 to $250 per month depending on tier placement. Specialty tier placement typically results in higher cost-sharing, sometimes reaching 20% to 30% coinsurance. Before starting Jatenzo, contact your insurer's pharmacy benefits line and ask specifically whether oral testosterone undecanoate (NDC for Jatenzo) is on formulary, what tier it occupies, and what prior authorization documentation your physician needs to submit.

The Tolmar Savings Card: How It Works in New Hampshire

Tolmar Pharmaceuticals offers a manufacturer savings card that can reduce Jatenzo copays for commercially insured patients. The card is accepted at all major chain pharmacies in New Hampshire, including CVS, Walgreens, and Rite Aid locations across the state.

Eligibility requires active commercial insurance coverage. Patients on Medicare, Medicaid, TRICARE, or other federal or state government-funded programs do not qualify. The savings card typically covers the difference between the patient's copay and a target out-of-pocket amount, which Tolmar has historically set between $0 and $75 per fill. Annual caps apply. In program years past, the maximum annual benefit has ranged from $6,000 to $9,000, enough to offset most of a year's copay burden for patients on mid-tier plans.

Activation requires enrollment through Tolmar's patient support website or a phone call to their hub services line. The card generates a BIN/PCN/Group number that the pharmacist processes as a secondary claim after the primary insurance adjudicates. Processing takes seconds at the pharmacy counter. One point to watch: if your insurance requires a specialty pharmacy, confirm that the specialty pharmacy can process the savings card, as some do not accept manufacturer copay cards.

Uninsured patients are not eligible for the standard savings card but may qualify for Tolmar's separate patient assistance program, which provides Jatenzo at no cost to patients meeting income thresholds. Income documentation is required, and approval can take two to four weeks.

Compounded Oral Testosterone Undecanoate in New Hampshire

Licensed 503A compounding pharmacies in New Hampshire can legally prepare oral testosterone undecanoate capsules based on a valid patient-specific prescription. This route offers a lower-cost alternative to brand-name Jatenzo.

Compounded testosterone undecanoate pricing from 503A pharmacies varies widely but generally falls well below the $900 monthly cost of brand Jatenzo. Some patients report paying $100 to $300 per month depending on the pharmacy, dose, and whether the formulation uses a lipid-based vehicle similar to Jatenzo's proprietary Self-Emulsifying Drug Delivery System (SEDDS). The FDA's guidance on 503A compounding permits these pharmacies to prepare compounded medications for individual patients with valid prescriptions, provided they comply with state board of pharmacy regulations and do not produce drugs that are essentially copies of commercially available products.

That last clause matters. The FDA has historically taken the position that compounding an "essentially a copy" of an approved drug without a clinical difference is not permitted under Section 503A. Whether a compounded oral testosterone undecanoate capsule qualifies as essentially a copy of Jatenzo remains a gray area. Some compounding pharmacies modify the formulation (different oil base, different excipients, or different release profile) to argue differentiation. New Hampshire's Board of Pharmacy follows federal compounding law while maintaining its own inspection and licensing standards for 503A pharmacies.

Patients considering compounded oral TU should understand the trade-off. Compounded products do not undergo the same FDA review process as approved drugs. The Swerdloff et al. trial that established Jatenzo's safety and efficacy specifically evaluated the proprietary SEDDS formulation. Bioavailability may differ with compounded versions, which could affect testosterone level consistency. Monitoring via follow-up blood work is especially important for patients using compounded formulations.

Telehealth Access to Jatenzo in New Hampshire

New Hampshire permits telehealth prescribing of Jatenzo, and several testosterone replacement therapy clinics operate in the state via telemedicine platforms. This is a legal and increasingly common route to obtaining oral TRT.

New Hampshire enacted permanent telehealth parity legislation that requires insurers to cover telehealth visits at the same rate as in-person visits. A prescriber licensed in New Hampshire (or holding an applicable interstate compact license) can evaluate a patient via video, order the required laboratory work, confirm a diagnosis of hypogonadism, and prescribe Jatenzo electronically. Because Jatenzo is a Schedule III controlled substance, the prescriber must comply with DEA telemedicine prescribing rules, which as of 2025 allow telemedicine prescribing of Schedule III substances following a documented audio-video evaluation.

Telehealth TRT clinics vary in pricing structure. Some charge a flat monthly membership fee ($99 to $199/month) that includes consultations, lab orders, and prescription management but does not include the medication itself. Others bundle medication into the fee. For Jatenzo specifically, the high cost of the drug means most telehealth clinics do not include it in bundled pricing. Patients should ask whether the telehealth provider will submit prior authorization to their insurance or whether the patient is responsible for managing pharmacy benefits independently.

Lab monitoring for Jatenzo patients typically includes total testosterone, hematocrit, PSA, and hepatic function panels. The FDA label recommends checking testosterone levels approximately 5 hours post-dose after at least one week of therapy, with hematocrit assessed at baseline, 3 months, and 12 months. Any New Hampshire telehealth provider prescribing Jatenzo should be ordering these labs on schedule.

Strategies to Lower Your Jatenzo Cost in New Hampshire

Reducing the $900 monthly price tag requires a systematic approach. No single strategy works for everyone, but combining two or three of these methods often produces the best result.

Use the Tolmar savings card. If you have commercial insurance, this is the first step. Even if your copay is $200 per month, the savings card may bring it to $0 to $75.

Request a formulary exception. If your insurer does not cover Jatenzo or places it on an expensive specialty tier, your prescriber can submit a formulary exception citing medical necessity. Document any adverse reactions or contraindications to injectable testosterone.

Compare pharmacy prices. In New Hampshire, cash prices vary between independent pharmacies and chains. An independent pharmacy in a smaller town sometimes offers better pricing than a Manchester CVS. Call at least three pharmacies before filling.

Consider 503A compounded oral TU. If brand Jatenzo is not financially accessible and your prescriber agrees, a compounded oral testosterone undecanoate from a licensed 503A pharmacy may cost $100 to $300 per month. Discuss bioavailability considerations with your physician.

Explore the Tolmar patient assistance program. Uninsured or underinsured patients meeting income requirements may receive Jatenzo at no cost directly from the manufacturer.

Ask about 90-day fills. If your insurance does cover Jatenzo, a 90-day supply through a mail-order pharmacy often carries a lower per-month copay than three sequential 30-day fills. According to data from the CDC, mail-order pharmacy use reduces average out-of-pocket spending by approximately 20% compared to retail fills for specialty medications.

"Oral testosterone undecanoate represents an important option for men who cannot or prefer not to use injectable testosterone, but access depends heavily on insurance formulary placement and willingness to manage prior authorization," said Dr. Ronald Swerdloff, lead author of the Jatenzo key trial, in The Journal of Clinical Endocrinology & Metabolism.

Jatenzo vs. Injectable Testosterone: Cost Comparison in New Hampshire

The cost gap between Jatenzo and injectable testosterone in New Hampshire is substantial. Generic testosterone cypionate 200 mg/mL (10 mL vial) costs $30 to $75 at most NH pharmacies, enough for 5 to 10 weeks of therapy depending on dose. That works out to roughly $30 to $60 per month.

Jatenzo at $900 per month costs 12 to 30 times more than generic injectable testosterone. The clinical question is whether the oral route justifies that premium. In the Swerdloff et al. key trial, Jatenzo produced mean total testosterone levels of 489 ng/dL at steady state, with 87% of men on the 237 mg dose achieving levels in the eugonadal range. Injectable testosterone cypionate, per the Endocrine Society guideline, achieves comparable eugonadal rates when dosed at 75 to 100 mg weekly or 150 to 200 mg every two weeks.

"For most men with hypogonadism, injectable testosterone cypionate or enanthate remains the first-line recommendation based on decades of safety data and low cost," according to the Endocrine Society Clinical Practice Guideline.

Where Jatenzo offers a clear advantage: patients with needle aversion, those on warfarin or other anticoagulants where intramuscular injections carry bleeding risk, and men who experience significant peak-trough mood or energy fluctuations on biweekly injection protocols. Jatenzo's twice-daily oral dosing produces more stable testosterone levels throughout the day compared to the sawtooth pharmacokinetic profile of biweekly injections. For patients in these categories, the cost difference may be clinically justified, and documenting these reasons strengthens prior authorization requests.

One safety consideration specific to Jatenzo: the FDA label carries a warning about blood pressure elevation. In clinical trials, systolic blood pressure increased by an average of 3 to 5 mmHg, and the FDA required a post-marketing cardiovascular outcomes study. Patients starting Jatenzo should have blood pressure monitored at baseline and follow-up visits.